Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT
Founder-led company
Phathom Pharmaceuticals stock price today
$10.55
+2.37
+28.97%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Phathom Pharmaceuticals stock price monthly change
-29.79%
month
Phathom Pharmaceuticals stock price quarterly change
-29.79%
quarter
Phathom Pharmaceuticals stock price yearly change
-11.66%
year
Phathom Pharmaceuticals key metrics
Market Cap | 490.26M |
Enterprise value | 281.67M |
P/E | -1.54 |
EV/Sales | N/A |
EV/EBITDA | -1.65 |
Price/Sales | N/A |
Price/Book | -4.54 |
PEG ratio | 0.05 |
EPS | -4.40 |
Revenue | N/A |
EBITDA | -202.98M |
Income | -246.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePhathom Pharmaceuticals stock price history
Phathom Pharmaceuticals stock forecast
Phathom Pharmaceuticals financial statements
| Jun 2023 | 0 | -40.96M | |
|---|---|---|---|
| Sep 2023 | 0 | -43.24M | |
| Dec 2023 | 682K | -79.57M | -11667.16% |
| Mar 2024 | 1.91M | -82.85M | -4333.26% |
| Mar 2024 | 1.91M | -82.85M | -4333.26% |
|---|---|---|---|
| Sep 2025 | 49.8M | -42.39M | -85.14% |
| Oct 2025 | 49.8M | -46.11M | -92.6% |
| Dec 2025 | 59.3M | -38.52M | -64.97% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 265039000 | 247.43M | 93.36% |
|---|---|---|---|
| Sep 2023 | 236992000 | 254.76M | 107.5% |
| Dec 2023 | 413842000 | 486.60M | 117.58% |
| Mar 2024 | 356499000 | 505.00M | 141.66% |
| Jun 2023 | -22.2M | -6K | 141.50M |
|---|---|---|---|
| Sep 2023 | -31.91M | -939K | 13K |
| Dec 2023 | -43.79M | -475K | 211.99M |
| Mar 2024 | -69.02M | -40K | 9.9M |
Phathom Pharmaceuticals alternative data
| Aug 2023 | 112 |
|---|---|
| Sep 2023 | 112 |
| Oct 2023 | 112 |
| Nov 2023 | 112 |
| Dec 2023 | 112 |
| Jan 2024 | 112 |
| Feb 2024 | 112 |
| Mar 2024 | 452 |
| Apr 2024 | 452 |
| May 2024 | 452 |
| Jun 2024 | 452 |
| Jul 2024 | 452 |
Phathom Pharmaceuticals other data
31.94%
-41.14%
of PHAT is owned by hedge funds
51
-35
12.49M
-15.87M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2024 | 0 | 49074 |
| Dec 2024 | 22500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KARBE FRANK director | Common Stock | 12,500 | $7.93 | $99,088 | ||
Purchase | PARIKH ASIT director | Common Stock | 10,000 | $8.13 | $81,250 | ||
Sale | NABULSI AZMI officer: Chief Op.. | Common Stock | 10,901 | $11.72 | $127,760 | ||
Sale | HENDERSON MOLLY officer: CFO and CBO | Common Stock | 4,325 | $11.72 | $50,689 | ||
Sale | CURRAN TERRIE director, officer.. | Common Stock | 33,848 | $11.72 | $396,699 | ||
Sale | HENDERSON MOLLY officer: CFO and CBO | Common Stock | 811 | $7.8 | $6,326 | ||
Sale | HENDERSON MOLLY officer: CFO and CBO | Common Stock | 11,681 | $8.95 | $104,545 | ||
Sale | HENDERSON MOLLY officer: CFO and CBO | Common Stock | 1,960 | $11.41 | $22,368 | ||
Sale | HENDERSON MOLLY officer: CFO and CBO | Common Stock | 2,110 | $12.87 | $27,164 | ||
Purchase | NABULSI AZMI officer: Chief Op.. | Common Stock | 10,000 | $8.26 | $82,600 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Phathom Pharma Is A Buy Before July PDUFA
Following Up On Phathom Pharmaceuticals
Phathom Pharma: Time To Take Profits (Rating Downgrade)
Phathom Pharma CRLs Present A Special Situation Opportunity
Phathom Pharma: Approved Drugs, Upcoming PDUFA, Smallish Addressable Market
Phathom Pharmaceuticals: Undiscovered Gem
Phantom Pharmaceuticals Could See Substantial Upside With 2 Upcoming Phase 3 Readouts
-
What's the price of Phathom Pharmaceuticals stock today?
One share of Phathom Pharmaceuticals stock can currently be purchased for approximately $10.55.
-
When is Phathom Pharmaceuticals's next earnings date?
Unfortunately, Phathom Pharmaceuticals's (PHAT) next earnings date is currently unknown.
-
Does Phathom Pharmaceuticals pay dividends?
No, Phathom Pharmaceuticals does not pay dividends.
-
How much money does Phathom Pharmaceuticals make?
Phathom Pharmaceuticals has a market capitalization of 490.26M.
-
What is Phathom Pharmaceuticals's stock symbol?
Phathom Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PHAT".
-
What is Phathom Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Phathom Pharmaceuticals?
Shares of Phathom Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Phathom Pharmaceuticals's key executives?
Phathom Pharmaceuticals's management team includes the following people:
- Ms. Terrie J. Curran Pres, Chief Executive Officer & Director(age: 56, pay: $865,850)
- Dr. Azmi Nabulsi M.D., M.P.H. Co-Founder & Chief Operating Officer(age: 66, pay: $727,970)
- Mr. David A. Socks Co-Founder & Director(age: 51, pay: $477,490)
-
Is Phathom Pharmaceuticals founder-led company?
Yes, Phathom Pharmaceuticals is a company led by its founders Dr. Azmi Nabulsi M.D., M.P.H. and Mr. David A. Socks.
-
How many employees does Phathom Pharmaceuticals have?
As Jul 2024, Phathom Pharmaceuticals employs 452 workers.
-
When Phathom Pharmaceuticals went public?
Phathom Pharmaceuticals, Inc. is publicly traded company for more then 5 years since IPO on 25 Oct 2019.
-
What is Phathom Pharmaceuticals's official website?
The official website for Phathom Pharmaceuticals is phathompharma.com.
-
Where are Phathom Pharmaceuticals's headquarters?
Phathom Pharmaceuticals is headquartered at 100 Campus Drive, Florham Park, NJ.
-
How can i contact Phathom Pharmaceuticals?
Phathom Pharmaceuticals's mailing address is 100 Campus Drive, Florham Park, NJ and company can be reached via phone at 877 742 8466.
Phathom Pharmaceuticals company profile:
Phathom Pharmaceuticals, Inc.
phathompharma.comExchange:
NASDAQ
Full time employees:
452
Industry:
Biotechnology
Sector:
Healthcare
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
100 Campus Drive
Florham Park, NJ 07932
Florham Park, NJ 07932
CIK: 0001783183
ISIN: US71722W1071
CUSIP: 71722W107
